Executive interview – InMed: Leading the way in the therapeutic development of cannabinol (CBN)

Executive interview – InMed: Leading the way in the therapeutic development of cannabinol (CBN)

InMed Pharmaceuticals — 14 videos in collection

More on this equity

In this video, InMed’s CEO Eric A Adams speaks about the company’s therapeutic development of cannabinol (CBN), a rare cannabinoid showing potential to treat serious diseases with high unmet needs. InMed is the first company to advance CBN into clinical trials for therapeutic development. Mr Adams also provides an update on the company’s programs in epidermolysis bullosa (EB) and glaucoma and its biosynthesis platform.

InMed is a biopharmaceutical company focused on manufacturing and developing cannabinoids. Its main pipeline product is INM-755 for epidermolysis bullosa, a serious, debilitating orphan indication.


You may also be interested in these:

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free